Literature DB >> 23354727

Osteoporosis in men: recent progress.

Robert A Adler1.   

Abstract

As osteoporosis in men has been recognized as an important clinical problem, new information is being accumulated on its scope, pathophysiology, evaluation, and treatment. Fracture risk calculators, such as FRAX, identify a large proportion of the older male population to be at heightened risk for fracture. The classification of osteoporosis into primary and secondary forms, while still useful, is affected by the fact that many men have multiple contributing factors to their fracture risk. The role of sex steroids is being better defined as other risk factors for fracture are delineated. As longevity continues to increase in men and until osteoporotic fracture is truly recognized as a potentially fatal disorder, many men will be undiagnosed and untreated. Two recent studies provide more evidence that treatments which decrease fracture risk in women do the same in men. With the publication of guidelines and increasing strength of evidence for treatment efficacy, it is hoped that more men will be evaluated and treated for this often neglected disorder.

Entities:  

Mesh:

Year:  2013        PMID: 23354727     DOI: 10.1007/s12020-013-9880-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  64 in total

1.  Effect of testosterone treatment on bone mineral density in men over 65 years of age.

Authors:  P J Snyder; H Peachey; P Hannoush; J A Berlin; L Loh; J H Holmes; A Dlewati; J Staley; J Santanna; S C Kapoor; M F Attie; J G Haddad; B L Strom
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

2.  Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.

Authors:  S Khosla; L J Melton; E J Atkinson; W M O'Fallon
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

3.  Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.

Authors:  Johann D Ringe; Alfred Dorst; Parvis Farahmand
Journal:  Arzneimittelforschung       Date:  2010

Review 4.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

5.  Fracture risk associated with the use of morphine and opiates.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  J Intern Med       Date:  2006-07       Impact factor: 8.989

Review 6.  Laboratory testing for secondary osteoporosis evaluation.

Authors:  Robert A Adler
Journal:  Clin Biochem       Date:  2012-02-04       Impact factor: 3.281

7.  Osteoporosis in men: the value of laboratory testing.

Authors:  C S Ryan; V I Petkov; R A Adler
Journal:  Osteoporos Int       Date:  2010-10-09       Impact factor: 4.507

8.  Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study.

Authors:  Troels Isaksen; Christian Stoltz Nielsen; Signe Engkjær Christensen; Peter H Nissen; Lene Heickendorff; Leif Mosekilde
Journal:  Calcif Tissue Int       Date:  2011-07-22       Impact factor: 4.333

9.  Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study.

Authors:  Gideon Sartorius; Sasa Spasevska; Amanda Idan; Leo Turner; Elise Forbes; Anna Zamojska; Carolyn A Allan; Lam P Ly; Ann J Conway; Robert I McLachlan; David J Handelsman
Journal:  Clin Endocrinol (Oxf)       Date:  2012-11       Impact factor: 3.478

Review 10.  Skeletal and extraskeletal actions of denosumab.

Authors:  Kathrin Sinningen; Elena Tsourdi; Martina Rauner; Tilman D Rachner; Christine Hamann; Lorenz C Hofbauer
Journal:  Endocrine       Date:  2012-05-13       Impact factor: 3.633

View more
  9 in total

Review 1.  Utility of the trabecular bone score (TBS) in secondary osteoporosis.

Authors:  Fabio M Ulivieri; Barbara C Silva; Francesco Sardanelli; Didier Hans; John P Bilezikian; Renata Caudarella
Journal:  Endocrine       Date:  2014-05-23       Impact factor: 3.633

Review 2.  Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

3.  Sex hormone-binding globulin (SHBG) as an independent determinant of bone mineral density (BMD) among Chinese middle-aged and elderly men.

Authors:  Xiao-Yun Zha; Yu Hu; Xiao-Na Pang; Ji-Heng Zhu; Gui-Lin Chang; Li Li
Journal:  Endocrine       Date:  2014-01-10       Impact factor: 3.633

Review 4.  Osteoporosis diagnosis in men: the T-score controversy revisited.

Authors:  Neil Binkley; Robert Adler; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

5.  Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.

Authors:  J Pepe; A M Isidori; M Falciano; G Iaiani; A Salotti; D Diacinti; R Del Fiacco; E Sbardella; C Cipriani; S Piemonte; O Raimo; P Biondi; F Biamonte; A Lenzi; S Minisola
Journal:  Endocrine       Date:  2014-08-08       Impact factor: 3.633

6.  Natural course of hypogonadism diagnosed during hospitalization in aged male patients.

Authors:  P Iglesias; F Prado; A Muñoz; M T Guerrero; M C Macías; E Ridruejo; P Tajada; C García-Arévalo; J J Díez
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

Review 7.  The clinical epidemiology of male osteoporosis: a review of the recent literature.

Authors:  Tina Willson; Scott D Nelson; Jonathan Newbold; Richard E Nelson; Joanne LaFleur
Journal:  Clin Epidemiol       Date:  2015-01-09       Impact factor: 4.790

8.  Effects of weight training time on bone mineral density of patients with secondary osteoporosis after hemiplegia.

Authors:  Liang Han; Shu-Gang Li; Hong-Wei Zhai; Peng-Fei Guo; Wei Chen
Journal:  Exp Ther Med       Date:  2017-01-23       Impact factor: 2.447

Review 9.  Osteoporosis in men: epidemiology and treatment with denosumab.

Authors:  Kristel M Sidlauskas; Emily E Sutton; Michael A Biddle
Journal:  Clin Interv Aging       Date:  2014-04-08       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.